Aster CMI Hospital in association with Datar Cancer Genetics Launches Comprehensive Cancer Screening Programme
A simple blood test to diagnose 30 types of cancer To commemorate World Cancer Day 2022, Aster CMI Hospital in association with Datar Cancer Genetics, a leading cancer research company launched Comprehensive Cancer Screening Programme today.
A simple blood test to diagnose 30 types of cancer
To commemorate World Cancer Day 2022, Aster CMI Hospital in association with Datar Cancer Genetics, a leading cancer research company launched Comprehensive Cancer Screening Programme today. With an aim to help patients detect cancer at its early stage that can save lives and drastically reduce the cost of cancer treatment, the hospital is bringing in EasyCheck360 (multiple cancers), EasyCheck FemmeSafe (women’s) and EasyCheck Prostrate cancer screening tests. EasyCheck is a revolutionary, radiation-free, globally recognized simple blood test for early cancer detection. It is clinically validated by one of the world’s largest clinical trials registered with the WHO clinical Trial Registry brought to you by Datar Cancer Genetics.
EasyCheck360 is a simple blood test that can detect more than 30 cancers. It is intended to be performed annually as a screening test, in individuals without any symptoms suggestive of cancer and aged > 30 years. And it can help detect cancers early that originate in the Oral Cavity, Lung, Breast, Esophagus, Stomach, Liver, Pancreas, Gallbladder, Kidney, Ovary, Cervix, Prostate, Bladder and specified Sarcomas. EasyCheck-FemmeSafe for women can detect cancers early that originate in the Breasts, Ovaries, Endometrium and Cervix. FemmeSafe is the outcome of intensive research efforts of the last several years by internationally recognized scientists and doctors. EasyCheck prostrate is a blood test that can detect Prostate Cancer and it is intended to be performed annually as a screening test, in individuals with no symptoms.
The technique employed is a proprietary technology which is a pathbreaking innovation, designed to detect circulating tumour cells (CTC) and their clusters before they become symptomatic or clinically detectable. The tests analyse CTC in the peripheral blood of an individual, are intended to detect the presence of malignant cells and have been clinically proven to have 88.19% Sensitivity and 99% Specificity in detecting cancer.
Speaking on the launch of the Comprehensive Cancer Screening Programme and the need for early detection for cancer, Dr. Vijay Agarwal, Lead & Sr. Consultant – Medical Oncology & Haematology, Aster CMI Hospital said, “In India, every year 1.2 million cases of cancer are diagnosed which accounts for 7,60,000 deaths. Due to changes in lifestyle as well as other risk factors, these numbers are slated to increase in the future. When cancer care is delayed there is a lower chance of survival, greater problems associated with treatment and higher costs. Hence, early detection and providing timely treatment are important which can significantly improve survival rates. Early detection of cancer requires early diagnosis and screening. Early diagnosis focuses on detecting symptomatic patients as early as possible, while this screening consists of testing healthy individuals to identify those having cancers before any symptoms appear. I am sure that with the launch of this Comprehensive Cancer Screening Programme, one can avail to undergo testing which can help diagnose various types of cancers at the earliest.”
Speaking on the launch of EasyCheck360®: Breakthrough in Early Cancer Detection Ms. Samara Mahindra, Director, New Cancer Initiatives, Datar Cancer Genetics said, “Cancer has become a chronic disease and one which can be treated successfully if detected early. The key to beating cancer is screening and early detection. Early detection will lead to a high chance of survival in most cases. EasyCheck360® is a breakthrough test and will go a long way in helping witness a cancer free India”